Advancing Treatments for Chronic Kidney Disease and Rare Renal Disorders White Paper

Advancing Treatments for Chronic Kidney Disease and Rare Renal Disorders in Adults and Children

Chronic kidney disease (CKD) is a condition characterized by abnormalities of kidney structure or function, present for greater than three months. CKD is quite common in adults, with a significant rise in incidence of close to 30% over the last 30+ years. While appearance in children is extremely rare, those with CKD face many challenges, such as negative self-image, behavior and learning problems, delayed language and motor skills development, and delayed growth rate compared to their healthy peers.

In this paper, we discuss:

• An assessment of metadata from Clinicaltrials.gov and publications from Pubmed.gov to characterize clinical research trends in CKD over the last 20 years
• Our approach in comparing two 10-year time periods (2002-2011 and 2012-2021) in terms of numbers of studies, study phases, study populations, type of interventions and endpoints
• Possibilities for future trajectories for treatment

Authors:

• Andrew Bevan, MRes, CSci, CBiol, MRSB, executive director project management, peri- and post-approval interventional studies, Evidera, PPD clinical research business of Thermo Fisher Scientific
• Davide Garrisi, MSc, MBA, executive director project management, general medicine, PPD clinical research business of Thermo Fisher Scientific
• Carmichael Angeles, M.D., senior medical director, pharmacovigilance, medical and scientific services, PPD clinical research business of Thermo Fisher Scientific